HIV Research Centre

King's College Hospital is the UK's leading research centre for HIV-associated kidney disease. We conduct a range of clinical trials and observational cohort studies, and our areas of interest include:

  • the clinical epidemiology of HIV-associated kidney disease and kidney transplantation in HIV infection
  • the effects of antiretroviral therapy on the kidney
  • bone disease.

The centre also takes part in studies of liver disease, viral hepatitis and liver transplantation.

Take part in our research

If you are a patient who is interested in taking part in any of the following trials or studies, or you would like more information, email the research team at: caldecotresearch@kcl.ac.uk.

Clinical trials – currently recruiting

  • TAILoR: a study examining the effects of Telmisartan, an angiotensin-receptor blocker, on insulin resistance in HIV positive patients. Patients stable on antiretroviral therapy will receive Telmisartan for 48 weeks.
  • SUPA: an interventional study aimed at improving adherence to antiretroviral therapy in those starting antiretroviral therapy.
  • GS-0140: An intensive study examining the effects of four antiretroviral regimens on kidney function. The study involves six 10-hour visits and participants will receive £2,000 for their effort.
  • TMC-3013: a switch study for patients stable on Truvada and a protease inhibitor. Participants will receive a novel single tablet regimen (containing tenofovir, emtricitabine, darunavir and cobicistat).

Observational studies – currently recruiting

  • SUPA: a short questionnaire to assess risk factors for non-adherence to antiretroviral therapy.
  • POPPY: pharmacokinetics and clinical observations in people over 50. This study examines the effects of ageing and HIV infection on health.
  • PARTNER: a Europe-wide study for HIV positive men and their HIV negative male partners. Designed to learn more about the risks of HIV transmission.
  • SEROCONVERTORS: a natural history study of patients with a known (approximate) date of acquiring HIV infection.
  • aMASE (Advancing Migrant Access to Health Services in Europe): examines barriers to healthcare for migrants living in England.
  • Genetic of drug toxicity: aims to identify genetic risk factors for drug hypersensitivity.
  • IDEA: evaluates the role of novel diagnostics in patients suspected to have active tuberculosis.
  • Immune profiling of patients with tuberculosis or lymphoma.
  • CHIC Bioresource: establishing of a bioresource for future genetic studies.

Funding sources

  • NIHR
  • Industry: Gilead Sciences, Janssen, ViiV Healthcare, Merck

Publications

For further information see our full listing of peer-reviewed publications.

Contact details

Dr Frank Post, HIV research lead
Lucy Campbell, research manager
Tel: 020 7848 5776
Email: caldecotresearch@kcl.ac.uk